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Abstract
Background: Ewing sarcoma is the second most common bone tumor, occurring mainly in children and young
adults. It shows a typical primitive, small round cell morphology and a characteristic fusion oncogene involving
EWSR1 and members of the ETS family in most of the cases. Neuronal maturation after chemotherapy is a rare
phenomenon and we herein describe such an exceptional case.
Case presentation: An 8-year old boy was diagnosed with a Ewing sarcoma in the left femur. On biopsy the
morphology was typical and there was an EWSR1-FLI1 gene fusion. He underwent neo-adjuvant chemotherapy
and resection of the tumor. On microscopic evaluation, part of the tumor showed ganglioneuroblastoma-like
differentiation with expression of neuronal markers. The continued presence of EWSR1 rearrangement in both
the blue round cell component and the ganglioneuroblastoma-like component was shown by FISH analysis.
Conclusions: In conclusion, this case describes the possibility of a Ewing sarcoma to differentiate into a
ganglioneuroblastoma-like lesion after neo-adjuvant chemotherapy treatment; the prognostic value of this
phenomenon remains questionable.
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Background
Ewing sarcoma, first described by James Ewing in 1921,
is the second most common malignant bone tumor after
osteosarcoma. Occurring mainly in children and young
adults; it accounts for 3 % of childhood malignancies.
During the last decades, the 5 year overall survival has
improved up to 85 % for patients with localized disease
but is still only 30 % for patients with metastatic disease
[1, 2]. Ewing sarcomas are primitive small blue round
cell tumors of bone and soft tissue, characterized by the
expression of EWS-ETS fusion genes as a driver muta-
tion [3, 4].
Neural differentiation in Ewing sarcoma is a rare
phenomenon and has been described before in a few
cases [3, 5]. Here we present a case in which an Ewing
sarcoma shows ganglioneuroblastoma-like differentiation
after chemotherapeutic treatment.
Case presentation
An 8-year old boy with no previous relevant medical
history, presented with pain and a palpable mass in the
left upper thigh. MRI showed a ca. 10 cm large lesion in
the femur with soft tissue extension. There were no
signs of metastasis elsewhere. The patient received neo-
adjuvant chemotherapy by the Ewing 2008 protocol.
After 4 cycles of VIDE (vincristine, ifosfamide, doxorubicin
and etoposide) chemotherapy, a staging FDG-PET/CT-scan
was performed, showing tumor regression, however no
normalization of metabolic activity at the primary tumor
site. After 6 cycles of VIDE, resection of the femur
diaphysis was performed with reconstruction with a
vascularised fibula transplant. An optimal recovery has
been seen so far, with no sign of recurrence or meta-
static disease at 21 months after surgery.
Histology
Biopsy
The pretreatment biopsy (routinely formalin-fixed,
paraffin-embedded, decalcified and hematoxylin-eosin-
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stained) revealed microscopically a small blue round cell
tumor with necrosis. A panel of antibodies was applied
according to standard protocol (antibodies used can be
seen in Additional file 1). There was positive membran-
ous staining for CD99 and CD56, consistent with the
diagnosis of Ewing sarcoma. By RT-PCR, the presence of
the EWSR1-FLI1 fusion gene confirmed this diagnosis.
Resection specimen
Macroscopically, a 15 cm measuring femur bone and
surrounding soft tissue specimen, showed on the cut
surface a 10.5 cm large tumor with soft tissue extension.
Necrosis, cystic and myxoid changes as well as areas of
hemorrhage were present. Microscopy of the tumor
showed, beside the usual small blue round cell popula-
tion, maturated neuroblastoma-like cells and ganglion-
like cells against a fibrillary (neuropil-like) background
(Fig. 1). It was estimated that of the surviving tumor
load about 70 % showed neural differentiation. Again,
there was a membrane reactivity for CD99 in the primi-
tive population, whereas the ganglioneuroblastoma-like
component showed expression of neural markers,
a
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Fig. 1 Resection specimen showing ganglioneuroblastoma-like differentiation. a: Overview (2.5x) (b): 10x (c): 20x (d): 40x
a
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b
Fig. 2 Immunohistochemistry on resection specimen (40x) (a) HE showing a part of the tumor with both differentiated (neuronal and ganglion-like
cell) and small groups of primitive (typical Ewing) tumor cells (b) NF Highlights part of the differentiated tumor cells and the neuropil. The primitive
tumor cells are mainly negative (c) CD99 labels the primitive tumor cells, whereas the differentiated component is negative. d Neu-N shows strong
reactivity of the differentiated tumor cells and is negative in the primitive tumor cells
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including NF, Neu-N and GFAP. There was no S100
expression (Fig. 2). To confirm the continued presence
of the fusion gene FISH analysis was performed show-
ing rearrangement of EWSR1 in both the small blue
round cell component and the ganglioneuroblastoma-
like component.
Discussion
The cellular origin of Ewing sarcomas remains both
elusive and controversial. However, the immature
neural phenotype of many tumors, formerly known as
PNET [5, 6], along with their gene expression signa-
tures and their disposition to neural differentiation in
experimental models implicate a neural crest stem cell
genetic program as integral feature of pathogenesis of
Ewing sarcoma [7]. Therefore, it is not surprising that
patient material, at least in some cases, show (ganglio)
neuroblastoma-like morphology.
Delattre et al. and Burchill et al. described neuroblastoma-
like features in a few untreated Ewing sarcoma cases with
genetic confirmation [8, 9], which could be a diagnostic
pitfall.
On the other hand, our case and the reported cases by
Maeda et al. and Collini et al. show ganglioneuroblastoma-
like maturation after chemotherapy probably as treatment
effect (3,5).
Whereas Maeda et al. confirmed their diagnosis molecu-
larly only on biopsy material (5), Collini et al. demonstrated
the presence of the EWSR1-FLI1 fusion gene in both pre-
and post-treatment specimens, as we did in our case [3].
However, such cases are very rare, we didn’t find another
one when reviewing 26 cases from our archives. This is in
line with the results of Delattre et al. investigating a series
of more than 90 cases with two neuroblastoma-like in-
stances [8].
Maturation during chemotherapeutic treatment is a
more common finding in other primitive pediatric tumors
such as rhabdomyosarcoma and neuroblastoma [10–13].
Since neural maturation is very rare in Ewing sarcoma, the
prognostic value remains unclear in comparison to e.g.,
embryonal rhabdomyosarcoma where it is associated
with favorable outcome [10, 14]. At least the case by
Maeda et al. had a unfavorable outcome with metastatic
disease showing typical small blue round cell morphology
of Ewing sarcoma in contrast to our case with no signs of
recurrence or metastases at 21 month after surgery [5].
Conclusions
In conclusion, this case describes the possibility of a
Ewing sarcoma to differentiate into neural tissue after
neo-adjuvant chemotherapy treatment, the prognostic
value of this phenomenon remains questionable.
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